Baseline characteristics for INFRONT 3: A Phase 3 double blind, placebo[...]
Positive Phase III Results Show Xofluza Significantly Reduces the[...]
05/10/2023 | News release | Distributed by Public on 05/11/2023 13:40
Please select the service you want to use:
Smartlinks | NASA - The National Aeronautics and Space Administration | News | Science | Space Program | Politics and Policy | Government | National Government | Space Program | Space Agencies
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact